CoChat

Mitochondrial and Immunoallergic Injury Increase Risk of Positive Drug Rechallenge After Drug-Induced Liver Injury: A Systematic Review

Open access
Hunt, Christine M. · 2010 · Hepatology
Cited by 39

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

In prospective studies, drug rechallenge following drug-induced liver injury (DILI) is associated with up to 13% mortality,1 whereas retrospective case series report a 2% mortality rate across a broad range of drugs2 and a 51% mortality rate with halothane rechallenge.3 However, risk factors for severe liver injury with rechallenge are poorly characterized.1-4 Clinical outcomes following drug rechallenge appear to vary markedly by drug,2, 3, 5-7 suggesting that rechallenge risk may be related to drug-specific mechanisms of injury. Drug rechallenge is rarely deliberately performed due to potential fatalities.4 However, drug rechallenge may be considered in life-threatening disease, when no other treatments are available with informed consent and close follow-up. Because limited data on drug rechallenge are available, additional data are needed to enhance clinical decision making. The aim of this systematic analysis is to examine clinical outcomes and mechanisms of liver injury that may influence a drug's potential for serious or fatal injury following rechallenge. When compared with the initial liver injury, rechallenge injury occurs more rapidly (generally after days or weeks, but sometimes within hours of rechallenge).2 Rechallenge events commonly result in jaundice (64%), hospitalization (52%), or allergic/hypersensitivity features (39%).4 Most rechallenge events are inadvertent and hence preventable if initial DILI is accurately identified and clearly communicated to the patient. DILI results from the cumulative effects of oxidative stress, reactive metabolites, immune injury from protein adducts, inhibition or disruption of transporters or drug metabolism, mitochondrial impairment,8 loss of ion gradients and adenosine triphosphate (ATP), and activation of programmed cell death or necrosis.9 Intraindividual and environmental factors, inflammatory mediators, and glutathione stores further modulate the outcome of DILI. For example, diabetes increases the risk of acute liver failure,10 which may be related to diminished mitochondrial function.8, 10, 11 In addition, approximately 1 in 8,000 adults harbor inherited pathogenic mitochondrial DNA mutations.12 Most drugs withdrawn from the market are mitochondrial toxicants, as are more than half of marketed drugs with black box warnings for hepatotoxicity or cardiotoxicity.13 Mitochondria are the key cellular energy source, supplying more than 90% of cellular ATP.13 Therefore, drug-induced mitochondrial impairment directly affects hepatocyte viability.8 Mitochondrial energy is largely generated by fatty acid oxidation; mitochondrial respiration also generates reactive oxygen species.13 Drugs or metabolites that inhibit the mitochondrial electron transport chain increase reactive oxygen species and can trigger the mitochondrial permeability transition (depleting the mitochondrial membrane potential difference), resulting in cell death.8, 13 Nucleoside analogues for treatment of human immunodeficiency virus inhibit mitochondrial DNA synthesis in a concentration-dependent fashion, resulting in decreased mitochondrial respiration and ATP and increased lactate.13 Drugs that are lipophilic and cationic (such as tacrine) accumulate in mitochondria and increase the risk of mitochondrial toxicity.13 Cell death occurs when a critical number of a hepatocyte's mitochondria are disabled.8 Upon withdrawal of mitochondrial toxicants, mitochondria can successfully regenerate over one to several weeks.14, 15 The likelihood of DILI is significantly increased in patients exhibiting polymorphisms of mitochondrial DNA polymerase gamma,16, 17 superoxide dismutase 2 (which scavenges mitochondrial superoxide),18 or specific human leukocyte antigen (HLA) markers associated with immunoallergic injury.19-23 Immunoallergic injury or hypersensitivity is associated with fever, rash, eosinophilia, and antidrug antibodies and occurs rapidly on rechallenge (sometimes within hours). Immunoallergic injury is initiated when a reactive drug or metabolite binds to intracellular proteins and generates a hapten, which is taken up by antigen-presenting cells and presented with major histocompatibility complex to helper T cells, and further activated by a danger signal of cytokines, such as high mobility group box 1 or other markers of necrosis or inflammation, to stimulate an immune response.24 Among the potential mechanisms of hepatotoxicity, concomitant mitochondrial impairment and immunoallergic injury appear most likely associated with fatal or positive rechallenge. Drug-specific rechallenge outcomes were systematically reviewed to examine the hypothesis that drug-related mitochondrial impairment and/or immunoallergic injury may particularly increase the risk of positive rechallenge or fatality and to further assess other rechallenge risk factors. With mitochondrial injury, rechallenge within several weeks of the primary DILI would be expected to greatly increase the risk of positive or fatal recha

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.24022

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 39

Metadata

Authors
Hunt, C. M.
Venue
Hepatology
Published
2010-12
Volume
52
Issue
6
Pages
2216-2222
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1981566552
Cited by
39
References
5
FWCI
3.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mitochondrial and Immunoallergic Injury Increase Risk of Positive Drug Rechallenge After Drug-Induced Liver Injury: A Systematic Review. https://app.cochat.ai/papers/10.1002/hep.24022
The paper
Hunt, C. M. (2010). Mitochondrial and Immunoallergic Injury Increase Risk of Positive Drug Rechallenge After Drug-Induced Liver Injury: A Systematic Review. Hepatology. https://doi.org/10.1002/hep.24022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.